ALBUQUERQUE, N.M.--(BUSINESS WIRE)--SolaranRx, a privately held biotechnology company developing a new class of precision medicine for the treatment of metastatic melanoma, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. SolaranRx and the NCI will work together to advance SolaranRx’s Precision Theranostic Platform™ that employs radiopharmaceutical therapies and companion imaging agents for metastatic melanoma, the most lethal form of skin cancer and highly resistant to current therapies.
Under the CRADA, the two parties will jointly evaluate SRX-1177, SolaranRx’s proprietary lead compound in preclinical mouse models of metastatic melanoma. SolaranRx’s technology precisely targets deadly melanoma tumors with its novel radiolabeled peptide that specifically binds to melanocortin-1 (MC1) receptors over-expressed in about 80 percent of human melanomas.
NCI’s Center for Advanced Preclinical Research (CAPR)’s group will work with SolaranRx to achieve the CRADA goals. SolaranRx CEO Les Stewart will serve as the collaborator principal investigator. CAPR conducts comprehensive preclinical studies to evaluate efficacy of therapeutics and diagnostics for human cancers.
Read more: http://www.businesswire.com/news/home/20160107005910/en/SolaranRx-Signs-Research-Agreement-National-Cancer-Institute